CLAIMS

We claim: 1

A method for determining down-regulation of gene expression of a human

- immunodeficiency virus (HIV) coreceptor, comprising the steps of: 3
- 4 culturing H9 T lymphoma or U937 promonocyte cells; a.
- electroporating said H9 or said U937 cells to introduce Product R into said 5 b.
- 6 H9 or said U937 cells;
- 7 culturing said electroporated H9 or said U937 cells; c.
- preparing total RNA from said H9 or said U937 cells after the step c; 8 d.
- reverse-transcribing the mRNA of said HIV coreceptor by a reverse 9 e.
- transcription-polymerase chain reaction (RT-PCR); and 10
- f. 11 measuring said RT-PCR product.
- 2. 1 The method of claim 1, wherein said HIV coreceptor is CCR5.
- The method of claim 1, wherein said step f further comprises the step of
- electrophorizing said RT-PCR.

09/257, 739 Hirschman etal 2/25/99

- 57 cong.
- The method of claim 1, wherein said electroporated H9 or U937 cells are
- 2 cultured for about 14 hours to about 18 hours.
- 1 5. A method fox reducing the amount of HIV coreceptor CCR5 in a patient
- 2 having HIV infection, comprising parenterally administering an effective HIV coreceptor
- 3 CCR5 reduction amount of Product R to said patient.
- 1 6. A method for preventing a patient from being infected by HIV, comprising
- 2 parenterally administering an effective HIV coreceptor CCR5 reduction amount of Product R
- 3 to said patient.

\$ 655